IMPORTANCE Sleep apnea (obstructive and central) is associated with adverse cardiovascular risk factors and increased risks of cardiovascular disease. Positive airway pressure (PAP) provides symptomatic relief, whether delivered continuously (CPAP) or as adaptive servo-ventilation (ASV), but the associations with cardiovascular outcomes and death are unclear.
Trial Inclusion Criteria
All RCTs assessing the association of PAP compared with standard care (or sham PAP) among adults (aged ≥18 years) with obstructive sleep apnea (OSA) or central sleep apnea (CSA) were potentially eligible for inclusion. Duplicate reports, trials that lasted 12 weeks or less, trials with less than 100 patient-years of follow-up per randomized group, and trials that did not report on outcomes of interest (cardiovascular events or death) were excluded. We also excluded scientific reports that presented pooled trial data for which the individual trials could not be identified to prevent double counting.
Study Selection and Data Extraction
The review of potentially eligible scientific reports identified by the searches was completed by 2 authors (J.Y. and Z.Z.) to identify reports for review in full text. Each full-text article was then reviewed for eligibility by these authors and, for each included study, data were extracted independently and in duplicate using a standardized electronic form. Any disagreement in extracted data was settled by consultation. Data sought were the first author, year of publication, country where the study was conducted, number of participants, percent of male participants, mean age of participants, inclusion criteria for OSA or CSA, intervention type, participant adherence, follow-up duration, cardiovascular events, and deaths (including cardiovascular death, noncardiovascular death, and all-cause death).
Two investigators (J.Y. and Z.Z.) also judged the quality of each included trial according to the Cochrane Collaboration's tool for assessing risk of bias. There were 7 quality items assessed: (1) random sequence generation, (2) allocation sequence concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) completeness of outcome data, (6) selective reporting, and (7) other sources of bias, which were each classified as low, unclear, or high. 13 
Outcomes
The composite outcomes of interest were major adverse cardiovascular events (cardiovascular death, nonfatal acute coronary syndrome [ACS] , and nonfatal stroke) and major adverse cardiovascular events with hospitalization for unstable angina. weighted mean differences were calculated using end-of-trial mean (SD) values and treatment group size. A 2-sided P value of less than or equal to .05 was deemed significant. The percentage of variability across the pooled estimates attributable to heterogeneity beyond chance was estimated using the I 2 statistic 13 and by calculating the P value for heterogeneity.
An I 2 statistic 13 was considered to reflect low likelihood (0%-25%), moderate likelihood (26%-75%), and high likelihood (76%-100%) of differences beyond chance, as was a P value of less than or equal to .05 for heterogeneity.
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Where there was a moderate or high likelihood of differences beyond chance, sensitivity analyses were done excluding individual studies to try and obtain an understanding of the reasons for the differences. Random-effects meta-regression analyses were used to investigate the associations of length of follow-up, adherence to randomized treatment, and apnea-hypopnea index with the observed RR for each trial. Subgroup analyses were done by grouping trials according to adherence to PAP (<4 vs ≥4 h/d), type of sleep apnea (OSA vs CSA), type of intervention (CPAP vs ASV), and whether vascular outcomes or death were prespecified outcomes. Evidence of publication bias was sought using the Egger regression test for funnel asymmetry in addition to visual inspection of the funnel plots. Statistical analyses were performed with Stata, version 12.0.
Results

Search Results and Characteristics of Included Studies
The literature search yielded 5765 articles of which 103 were reviewed in full text ( Figure 1 ). Diagnosis of sleep apnea was based on conventional polysomnographic or polygraphic monitoring in all but 1 trial that used a home sleep study. 24 Mean or median adherence to the intervention ranged between 1.4 hours per day 20 and 6.6 hours per day. 25 The assessments of risk of bias (eFigure 1 in the Supplement) showed that only 1 trial 19 included blinding of participants and personnel to the intervention, but all except 1 did blinded assessment of cardiovascular outcomes. 23 Funnel plots and Egger regression tests identified no strong evidence of publication bias with just 1 significant result for major adverse cardiovascular events (P = .03) (eFigure 5 in the Supplement).
Association of PAP With Cardiovascular Outcomes and Death
There were no associations of PAP with major adverse cardiovascular events (RR, 0.77 [95% CI, 0.53 to 1. Box sizes are proportional to study weight (box center positioned at point estimate of effect). Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to heterogeneity beyond chance (0%-25%, low likelihood; 26%-75%. moderate likelihood; 76%-100%, high likelihood), and the P value is for a test of heterogeneity across all studies (P value <.05 indicates likely variation across pooled estimates beyond chance). If 0 events were reported for 1 cell in a comparison, a value of 0.5 was added to both cells automatically before calculating the risk ratio (95% CI). Risk ratio data are rounded to 2 decimal places but plotted to exact values.
a Major adverse cardiovascular events consist of cardiovascular death, nonfatal acute coronary syndrome, and nonfatal stroke.
b Plus indicates major adverse cardiovascular events in addition to hospitalization for unstable angina.
for cardiovascular death (P = .45), all-cause death (P = .33), or noncardiovascular death (P = .73) ( Figure 5 ). There were no subgroup analyses that showed clear evidence of heterogeneity between subgroups of studies (all P values for homogeneity were >.09), but the summary RR for the 4 trials that achieved at least 4 hours of adherence did have a 95% CI that just excluded unity (RR, 0.58 [95% CI, 0.34 to 0.99]).
Association of PAP With Intermediate Outcomes
Data describing the associations of PAP with intermediate outcomes were diverse and inconsistently described. Comparable data reported by more than 1 study ranged in quantity from sleepiness reported by 5 studies 17,19,20,22,24 (n = 4285 participants) to total cholesterol reported by just 2 studies 18, 20 (n = 527 participants) ( Table 2) . For the included studies, there was no association of treatment with PAP detected for blood pressure, BMI, any lipid parameter, glycemia, or EQ-5D, but associations were observed for sleepiness and a range of measures of physical and mental well-being. For several of these intermediate measures, there was evidence of differences in the association with PAP across the contributing trials ( Table 2) .
Discussion
In this meta-analysis of RCTs, there were no significant associations between PAP treatment and a range of cardiovascular events or death, although anticipated associations with some other outcomes related to sleep apnea were observed.
7,32-35
Based on the available evidence, it is reasonable to recommend PAP therapy for the improvement of symptoms in patients with OSA but not for protection against vascular disease or death. It is possible that an enhanced evidence base able to better explore effects in patient subgroups might identify protective effects of PAP treatment for some patient subsets. In the meantime, these data emphasize the importance of proven therapies, such as blood pressure lowering, lipid lowering, and antiplatelet therapy in patients with sleep apnea, who should be treated according to established guidelines for patients at elevated cardiovascular risk.
36-38
Sleep apnea is highly prevalent [39] [40] [41] [42] [43] and is associated with an elevated risk of serious vascular outcomes 4 Box sizes are proportional to study weight (box center positioned at point estimate of effect). Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to heterogeneity beyond chance (0%-25%, low likelihood; 26%-75%. moderate likelihood; 76%-100%, high likelihood), and the P value is for a test of heterogeneity across all studies (P value <.05 indicates likely variation across pooled estimates beyond chance). If 0 events were reported for 1 cell in a comparison, a value of 0.5 was added to both cells automatically before calculating the risk ratio (95% CI). Risk ratio data are rounded to 2 decimal places but plotted to exact values.
Positive Airway Pressure, Cardiovascular Events, and Death in Sleep Apnea
Original There have been several reasons postulated for the failure of PAP trials to demonstrate protection against vascular outcomes. It is possible that the limited adherence to therapy in many trials was insufficient to drive protection, and there have been several reports of differential benefits of PAP in more vs less adherent patients derived from post hoc analyses.
17,25 A weakness of these reports is that analyses based on nonrandomized comparisons may reflect confounding due to differences between adherent and nonadherent individuals rather than their use of PAP. The methodologically more robust meta-regression approach reported herein identified no association of adherence with the effectiveness of PAP for prevention of vascular disease, although statistical power to detect modest effects was low. Likewise, there was no heterogeneity detected between the associations observed in subgroups of trials that achieve adherence less than 4 vs 4 or more hours per night. The statistically significant benefit (RR, 0.58 [95% CI, 0.34 to 0.99]) observed for the major adverse cardiovascular events outcome in trials with at least 4 hours per night may be interpreted as indicating the importance of good adherence to achieving benefits with PAP. However, the absence of any comparable association for other outcomes, the post hoc nature of the subgroup analyses, and the multiple comparisons made also make chance a plausible explanation. The short follow-up duration of most trials may have given insufficient time for PAP to have affected vascular outcomes, 23 although the metaregression identified no association between follow-up time and the hazard ratio for PAP vs control in the contributing trials. It has been suggested that PAP may be ineffective in patients with advanced disease, but this has not been observed for other interventions targeting vascular conditions in which treatments have typically proven effective in primary and secondary prevention settings.
53-57
The absence of any significant association of PAP with intermediate markers of vascular risk in the trials included in this overview may explain the null associations of PAP with hard vascular outcomes. The disparity with earlier reports of protection for several intermediate markers of vascular risk 6,7,49,52,58 might reflect the small and inconsistently reported benefits in the prior studies and interpretation influenced by publication bias. It is also possible that differences in the characteristics of participants included in the present systematic review and meta-analysis, compared with prior studies, may account for the discrepancies, and this warrants further investigation. The positive association of PAP observed with the Epworth Sleepiness Scale (reported previously) 28 provides reassurance that PAP was delivered with sufficient integrity, in these Major adverse cardiovascular events comprise cardiovascular death, nonfatal acute coronary syndrome, and nonfatal stroke. Circle sizes indicate the weight given to each study (centered on the intersection of the RR for major adverse cardiovascular events on the y-axis and the mean trial value of the metric of interest on the x-axis). included trials, to deliver anticipated benefits. This overview also shows beneficial effects on anxiety, depression, and physical function (previously reported in the individual studies). These benefits are of importance to patients and support the use of PAP for treating sleep apnea even in the absence of evidence of vascular protection. Further investigation of the effects of PAP on these outcomes is warranted. The inclusion of 2 trials of patients with predominantly central sleep apnea helped to increase statistical power to address questions about the associations of PAP treatment with outcomes, while concurrently enabling formal investigation for evidence of different associations of PAP treatment in patients with different types of sleep apnea. The absence of evidence of heterogeneity of the associations between PAP treatment and outcomes across the obstructive sleep apnea and central sleep apnea subgroups, along with the absence of a significant association within either subgroup, strengthens the primary conclusion of no effect.
Research Original Investigation
This study has several limitations. First, the summary data represent the available evidence from moderate-to-largesized RCTs able to describe the association of PAP with vascular outcomes and death, but there are still relatively few events recorded. Most outcome events derived from a small number of studies, and many were from high-risk patient subsets. It is possible that more data might reveal moderate benefits of PAP that were beyond the power of this overview to detect, although the absence of improvement in intermediate risk markers makes this a low likelihood.
The second limitation, conversely, is that it is possible that additional data might reveal adverse effects since point estimates of the associations of PAP with vascular death and allcause death were suggestive of harm rather than benefit.
Third, the participants in the contributing trials were mostly those without excessive sleepiness, and it may be that effects of PAP on vascular outcomes are restricted to patients with more severe symptomatology. However, it is difficult to envisage how this hypothesis could be tested in a trial because PAP treatment is indicated for most individuals with more severe symptomatology, and randomization to a control group would not be feasible.
An ongoing trial of CPAP following ACS (NCT01335087) and one of ASV in patients with heart failure (NCT01128816) will provide additional insight, but the practical complexity and cost associated with conducting PAP trials make it unlikely that substantial additional data will be forthcoming in the near future. If a new and very well-tolerated method of delivering PAP becomes available, this may be worth evaluating in another large trial since it remains possible that strong adherence may produce benefits. In the meantime, the evidence from these RCTs suggests that the association of sleep apnea with vascular outcomes and death, seen in observational studies, may represent disease processes that cannot be ameliorated by PAP delivered at the average intensity achieved in these clinical trials or by currently feasible methods in clinical practice.
Conclusions
The use of PAP compared with no treatment or sham was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes. 
